Comparison of transcatheter arterial chemoembolization combined with radiofrequency ablation or microwave ablation for the treatment of unresectable hepatocellular carcinoma: a systemic review and meta-analysis
| Autor: | Menghao Cao, Yiping Wei, Wenxiong Zhang, Fengming Yi, Jingli Ding, Hongliang Luo, Jun Lei, Jianxin Wu, Jiani Zhao, Mengyu He |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Cancer Research
medicine.medical_specialty Carcinoma Hepatocellular Physiology Radiofrequency ablation unresectable hepatocellular carcinoma 030218 nuclear medicine & medical imaging law.invention 03 medical and health sciences 0302 clinical medicine law Physiology (medical) Medical technology Humans Medicine R855-855.5 Chemoembolization Therapeutic Microwaves Transcatheter arterial chemoembolization Radiofrequency Ablation business.industry Liver Neoplasms Microwave ablation Middle Aged medicine.disease meta-analysis Treatment Outcome surgical procedures operative microwave ablation 030220 oncology & carcinogenesis Hepatocellular carcinoma Catheter Ablation Radiology business therapeutics transcatheter arterial chemoembolization |
| Zdroj: | International Journal of Hyperthermia, Vol 37, Iss 1, Pp 624-633 (2020) |
| ISSN: | 1464-5157 0265-6736 |
| Popis: | Background Transcatheter arterial chemoembolization (TACE), radiofrequency ablation (RFA), and microwave ablation (MWA) are regarded as effective therapies for treating unresectable hepatocellular carcinoma (HCC). We conducted this study to compare the efficiency and safety of TACE combined with RFA (TR group) or MWA (TM group). Method PubMed, the Cochrane Library, Ovid Medline, Web of Science, Scopus, Embase, ScienceDirect, and Google Scholar were searched. The primary endpoints were overall survival (OS), progression-free survival (PFS), response rates, and complications. Result Eight cohort studies and one randomized controlled trial were included. The TM group had better OS (Hazard ratio [HR]: 1.55; 95% confidence interval [CI]: 1.09–2.21, p = 0.01) and a better 2- and 3-year OS rate, 24-month PFS rate (Risk ratio [RR]: 0.67; 95% CI: 0.46–0.96, p = 0.03), and complete response rate (RR: 0.87; 95% CI: 0.79–0.96, p = 0.003) than the TR group. Furthermore, the TM and TR groups did not show significant differences in PFS, the disease control rate or complications. The advantage of TM was mainly reflected in younger patients (50–60 years old) compared with patients aged 60–70 years, as well as in patients with larger tumors (≥3 cm) compared with patients with tumors |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|